Stéphane L. Bogen
Department of Medicinal Chemistry
Merck Research Labs
2015 Galloping Hill Road
Kenilworth
USA
Name/email consistency: high
- Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species. Bogen, S.L., Arasappan, A., Velazquez, F., Blackman, M., Huelgas, R., Pan, W., Siegel, E., Nair, L.G., Venkatraman, S., Guo, Z., Doll, R., Shih, N.Y., Njoroge, F.G. Bioorg. Med. Chem. (2010)
- Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles. Bogen, S.L., Pan, W., Ruan, S., Nair, L.G., Arasappan, A., Bennett, F., Chen, K.X., Jao, E., Venkatraman, S., Vibulbhan, B., Liu, R., Cheng, K.C., Guo, Z., Tong, X., Saksena, A.K., Girijavallabhan, V., Njoroge, F.G. J. Med. Chem. (2009)
- Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034. Bogen, S., Arasappan, A., Pan, W., Ruan, S., Padilla, A., Saksena, A.K., Girijavallabhan, V., Njoroge, F.G. Bioorg. Med. Chem. Lett. (2008)
- Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity. Bogen, S.L., Ruan, S., Liu, R., Agrawal, S., Pichardo, J., Prongay, A., Baroudy, B., Saksena, A.K., Girijavallabhan, V., Njoroge, F.G. Bioorg. Med. Chem. Lett. (2006)
- Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. Bogen, S.L., Arasappan, A., Bennett, F., Chen, K., Jao, E., Liu, Y.T., Lovey, R.G., Venkatraman, S., Pan, W., Parekh, T., Pike, R.E., Ruan, S., Liu, R., Baroudy, B., Agrawal, S., Chase, R., Ingravallo, P., Pichardo, J., Prongay, A., Brisson, J.M., Hsieh, T.Y., Cheng, K.C., Kemp, S.J., Levy, O.E., Lim-Wilby, M., Tamura, S.Y., Saksena, A.K., Girijavallabhan, V., Njoroge, F.G. J. Med. Chem. (2006)
- Hepatitis C virus NS3-4A serine protease inhibitors: use of a P2-P1 cyclopropyl alanine combination for improved potency. Bogen, S., Saksena, A.K., Arasappan, A., Gu, H., Njoroge, F.G., Girijavallabhan, V., Pichardo, J., Butkiewicz, N., Prongay, A., Madison, V. Bioorg. Med. Chem. Lett. (2005)
